… In the current study, CMV disease developed approximately 11 days sooner in the
seropositive recipients of placebo than in their seronegative counterparts. Therefore, since …

… ganciclovir can prevent new cytomegalovirus disease in patients with established
cytomegalovirus retinitis who are treated with a ganciclovir … ganciclovir. First, patients assigned to …

… CMV disease involving the central nervous system were randomly assigned to receive 6
weeks of intravenous ganciclovir … Twenty-one (84%) of 25 ganciclovir recipients had improved …

… resistance as a result of the advent of both routine oral ganciclovir … of ganciclovir-resistant
cytomegalovirus disease among transplant recipients who had received oral ganciclovir …

… ganciclovir treatment range from below 2% up to almost 10%, with a higher incidence in CMV
… is noninferior to intravenous ganciclovir for eradication of CMV disease in SOT recipients (…

… of acyclovir treatment for CMV after initial intravenous ganciclovir in previous reports (14), or
… least 3 months of ganciclovir or valganciclovir after initial intravenous ganciclovir treatment. …

… ganciclovir (6 mg/kg every 12 h) for 6 weeks [17, 18], demonstrating both virologic … CMV
disease involving the central nervous system (CNS) who are treated with intravenous ganciclovir …

… and preliminary studies suggest that it is effective in suppressing CMV retinitis in humans.In
this article, we report our experience using ganciclovir to treat 18 patients with CMV retinitis. …

… with ganciclovir/valganciclovir for congenital cytomegalovirus infection… cytomegalovirus
infection were treated with ganciclovir for 6 … congenital CMV infection with intravenous ganciclovir …

… that is similar to that with intravenous ganciclovir. Therapy with intravenous ganciclovir or oral
… treatment option for patients with symptomatic congenital CMV disease involving the CNS. …